The amino acid L-citrulline (CIT) is safely used from the neonatal period onwards in 2 those with urea cycle defects and carbamyl phosphate synthetase or ornithine 3 transcarbamylase deficiencies, but several lines of enquiry indicate that it might have a 4 much wider therapeutic role. 5
Its name is derived from citrullus the Latin name for watermelon. It was extracted in 1914 22 by Koga&Odake from watermelon (1) and identified by Wada in 1930. Of note, this 23 aminoacid is not incorporated into proteins (2) . 24
Glutamine is a precursor of ornithine, which can be converted to CIT by the intestine. 25
Arginine is also metabolized in CIT into enterocytes (2) . Because enterocytes do not 26 possess argininosuccinate synthase, CIT is released in the portal vein (3) . Since there only 27 small net CIT uptake by the liver (3) , in the presence of normal liver function, it enters the 28 systemic circulation and is then transformed in the kidney to ARG ( fig.1 ). CIT net 29 production at the whole body level is therefore almost exclusively from the epithelium of 30 small intestine (Fig 1) (2) . 31
CIT can act as ARG regulator as it can control delivery of ARG to the liver. Intestinal 32 arginase and ornithine carbamoyl transferase yield citrulline in proporsion to delivery of 33 dietary protein. Fasting leads to less CIT and proportionally more ARG reaching liver. 34 ARG has a major impact on hepatic enzymes and up to 5 fold increase in ureagenesis. 35
This effect needs to be regulated, hence the important role of CIT in this physiological 36 context (2, 3) 
37
These metabolic considerations explain why administration of CIT has been proposed to 38 increase systemic ARG concentrations. Of note, CIT is almost absent in food. Only 39 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
5 watermelon contains significant amounts of CIT; all parts of watermelon, rind, flesh and 40 seeds contain CIT in greatest amount, on a dry weight basis in the rind, which might offer 41 a convenient source of natural citrulline (4) 
42
In healthy individuals the plasma concentration of citrulline is about 40 µmol/L with 43 some racial variation (less in Chinese Asians) (5) .
44
CIT plasma concentration has been proposed as clinical tool for identification of small 45 bowel absorptive mass. Statistical significant correlations between plasma CIT 46 concentration and small bowel length as well as villous atrophy have been demonstrated. 47
CIT has been considered a reliable marker of intestinal malabsorption and its role in 48 clinical practice in currently under investigation (6) .
49
CIT as an organic supplement appears to be a powerful pharmaconutrient, and early 50 experimental studies have suggested its therapeutic potential to restore ARG metabolism 51 in critically ill patients with sepsis (7, 8) .
52
CIT exhibits good bioavailability (9) , thanks to its ability to be handled by a wide number 53 of amino acid transporters (10) . In the liver CIT is a metabolic intermediate involved in the 54 elimination of a toxic component (ammonia) through another which is non-toxic (urea) 55 (Fig.1) . Of note, CIT recycling in the urea cycle is mainly separated meaning that there is 56 neutral /balanced flux in the liver (3) (Fig 1) . The brain and some leukocytes can also 57 produce ARG from CIT (11) to a limited extent. 58
Oral CIT supplementation raises plasma ARG concentrations and augments nitric oxide 59 (NO)-dependent signalling proportionally (12) . Since CIT is not subject to pre-systemic 60 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 elimination in the liver whereas ARG is largely extracted there (13) (Fig. 1) CIT serves as 61 an ARG precursor more productively than ARG itself (2, 3, 12) . In most human studies, 62
CIT has been used as a supplement, intending this as a substrate from which ARG can be 63 synthesized or as a NO precursor. 64
CIT is indeed one of the key organic compound leading to production of NO in most 65 cells, NO synthase (NOS) enzymes catalysing the conversion of ARG into CIT, 66 producing NO in an internally conservative cycle (13) (fig 2) . Although intracellular ARG 67 concentrations are sufficient to saturate NOS, therapy with excess ARG can enhance NO 68 production because the CAT-2 ARG transporter is closely associated to NOS within the 69 cell membrane and both are co-stimulated by signals such as pro-inflammatory cytokines 70 (3) . In the situation of low protein intake, it is possible that the alternative pathway is 71 activated. To inhibit ARG derived ureagenesis and thus loss of proteins, intestinal 72 arginase and ornithine carbamoyl transferase are activated. This results in an increase in 73 prehepatic conversion of ARG to CIT, which (unlike ARG) passes more or less freely 74 through the liver and is released to the systemic circulation (2, 13, 14) .
75
CIT as dietary supplement appears to be a powerful pharmaconutrient, and early 76 experimental studies have suggested its therapeutic potential to restore ARG metabolism 77 in critically ill patients with sepsis (7, 8) . 78
79

Safety of citrulline administration 80
CIT is considered as safe for oral use (15) . It has no identified toxicity and is used as long-81
term replacement therapy for children with urea cycle defects. In contrast to ARG and 82 ornithine, which induce gastrointestinal side effects at moderate dosage (e.g. 10g in one 83 bolus) (16) , no side effects have been reported from CIT administration as an oral 84 supplement at doses up to 15g (9) . Additional safety data come from interventional 85
studies. 86
In a randomized placebo-controlled double-blind trial of orally administered CIT in 40 87 children undergoing repair of congenital cardiac defects no adverse events were noted (17) .
88
In a pharmacokinetic study of intravenously administered CIT no side effects or adverse 89 events were noted (18) . This pharmacokinetic study formed the basis for an on-going 90 randomized, placebo controlled, double-blind trial of intravenous CIT in children at above 91 average postoperative risk after surgery for congenital heart disease (19) . 92
CIT supplementation is now raising clinical interest for the treatment of paediatric 93 pulmonary hypertension however further controlled clinical trials are needed to drawn an 94 impactful conclusion (20) . 95
96
Effects on immunity, oxidative stress and related parameters 97 CIT administration reduces the number of total leukocytes and of neutrophils in 98 circulation (9) and might induce ARG-derived NO-mediated vasoprotection, with 99 inhibition of cell adhesion and leukocyte activation, and suppression of endothelial 100 damage ( Fig. 2 ) (21) . 101 and ADMA (22) (Fig 2) . 107
Citrulline mediated vasoprotection has now been demonstrated in a phase 2 study of 108 sickle cell disease (23) and further trials are on-going. 109
As further NO mediated effect with major changes in markers of oxidative stress was 110 demonstrated by supplementing a group of professional cyclists (21) with a single pre-race 111 dose of 6g CIT malate. Higher concentrations of neutrophil nitrite suggested that these 112 effects were mediated by NO (Fig. 2) , and there was no evidence of oxidative damage 113 (levels of malondialdehyde and creatine kinase, for example, remaining normal). 114
However, there is no definitive evidence that effects of CIT on immunity are mediated 115 through NO synthesis only. Polyamines derived from ARG and ornithine could also be 116 involved. Also, CIT has anti-oxidant properties, which could be involved in these effects. 117
118
Effects on sports performance and recovery 119
In addition to the study reported above (21) , several others are of interest in this field. Oral 120 CIT supplementation given for a week reduced the time needed to complete a cycle 121 ergometer exercise trial in healthy trained men in a double-blind randomized placebo
controlled 2-way crossover study (24) CIT supplementation significantly increased plasma 123 ARG levels and reduced the exercise time by 1.5 % (p < 0.05). This was associated with 124 subjective improvements in muscle fatigue and ability to concentrate immediately after 125
exercise. 126
The effects of CIT on NO biomarkers, pulmonary O 2 uptake (V O 2 ) kinetics, and exercise 127 performance were studied in a randomized, placebo-controlled, crossover study. Short-128 term CIT, but not ARG supplementation can improve V O 2 kinetics as expressed by V O 2 129 mean response time (59 ± 8 and 53 ± 5 s with placebo and CIT respectively, p<0.05) 130 during severe-intensity exercise, improving the tolerance (duration: 589s ± 101 vs 661s ± 131 107), and increasing the whole volume of work completed (25) .
132
A further preliminary study suggested that consuming CIT malate before competition has 133 the potential to improve some elements of performance in masters level female tennis 134 players (26) . In this lab-based study CIT yielded improved grip strength, peak and 135 explosive power compared to placebo. Direct application to "on court performance" is 136 requested to validate results. 137
A randomized double-blind cross-over study (27) examined the effect of a single 8g dose 138 of CIT malate on the performance of flat barbell bench presses (pectoral training) as an 139 anaerobic exercise and to test muscle soreness after this exercise. The study showed a 140 significant increase in the number of repetitions achieved (52% more in the 4 th set than in 141 the equivalent placebo session where 40mL lemon juice, 10 g powdered sugar, 60 mg 142 sodium saccharine, and tap water 200 mL were used) and there was a 40% decrease inM A N U S C R I P T
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10 muscle soreness at 24 and 48 hours (27) . A further randomized double-blind study (28) 144 examined the effect of a pre-exercise dose of CIT (6g), watermelon juice (to provide CIT 145 1g), or placebo (7.5% sucrose placebo drink) on the total number of repetitions completed 146 over 5 sets, time to exhaustion, maximal oxygen consumption (VO 2 max), anaerobic 147 threshold, and flow-mediated vasodilation. In this study pre-exercise supplementation 148 appeared to be ineffective in improving exercise performance (28) . 149
It thus appears that CIT may improve exercise performance in young healthy adults under 150 some conditions, but these acute effects still need further investigation (29) .
151
Of note, in several of these studies, CIT has been used as a malate salt, not as the native 152 amino acid. As malate is an intermediary of the Krebs cycle increasing cellular energy 153 production it is unclear whether the observed effects are due to malate, to CIT or to both. 154
There is no study comparing the effects of CIT malate and CIT. In Table 2 the doses of 155 citrulline from citrulline malate have been corrected to subtract the contribution of malate 156 in those cases where this salt was used. 157
158
MELAS syndrome 159
As CIT plays a key role in the production of NO in most cells, due to its great ability to 160 increase intracellular ARG availability, it has been used in children with the 161 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) 162 syndrome (30) . In a recent clinical study stable isotope infusion techniques were used to 163 assess NO production in children with MELAS syndrome and in healthy controls. In 164 M A N U S C R I P T
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children with MELAS syndrome, CIT supplementation resulted in important increases in 165 NO production, ARG flux, plasma ARG, and CIT flux, which were greater than obtained 166 with ARG supplementation (31) . In an earlier clinical trial (32) , the effect of ARG or CIT on 167 lactic acidaemia had been studied in adults with MELAS syndrome. Plasma lactate 168 decreased significantly after CIT supplementation, whereas the effect of ARG 169 supplementation did not reach statistical significance. These promising results justify 170 additional controlled trials to assess the therapeutic effects of CIT on clinical features and 171 complications of MELAS syndrome. 172
Cardiovascular diseases 173
In most of the work in the cardiovascular area, CIT has been given with the intention of 174 boosting levels of ARG and as a NO precursor. The conditions studied have therefore 175 included those where absolute or relative deficiencies of ARG and NO are known or 176 suspected, and include arteriosclerosis, pulmonary and systemic hypertension and cardiac 177 failure. In general, oral CIT is seen to improve cardiac performance with exercise. A 178 causal link is supported by the study on professional cyclists already referred to above (19) .
179
In a double-blind, randomized, placebo-controlled trial (33) 15 otherwise healthy middle-180 aged male subjects with evidence of early arteriosclerosis were given 5.6 g/day of CIT 181 (n=8) or placebo (n=7) for 7 days. Their initial arterial stiffness was abnormal, as 182 indicated by a brachial-ankle pulse wave velocity (baPWV) of >1400 cm/s. CIT 183 supplementation increased plasma CIT (p<0.05), plasma ARG (p<0.01), and the ratio ofM A N U S C R I P T
A C C E P T E D
these effects were all attenuated (each by 4 to 6 mmHg) (34) . (where 30 is the upper limit of normal). Testing was repeated after brief, experimentally 201 induced, digital ischaemia, and when ARG was given rather than CIT, and in both cases 202 similar improvements were seen at 60 days (35) , which suggests a common mechanism of 203 action, likely through NO production. 204
In a second paper (36) , on the same patients, the authors recorded the effects of CIT on 205
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13 pulmonary artery pressure, which fell by 16% (56.7 ± 7.96 mmHg to 47.7 ± 8.59 mmHg; 206 p<0.05) over 60 days in association with an improvement in right ventricular ejection 207 fraction, blood pressure and treadmill tolerance. ARG was equally effective, but required 208 the higher dose of 8 g (36) . This may be explained by the fact that ARG is metabolized in 209 splanchnic area whereas CIT is not (see above for details). 210
Another group of investigators recently reported that adults with heart failure had 211 improvements in left ventricular ejection fraction, functional class, and endothelial 212 function as assessed by photoplethysmography after treatment with oral CIT for 4 months 213 (37) .
214
Intensive CIT supplementation (oral or intravenous) was previously proposed as a 215 possible means of preventing post-operative pulmonary hypertension, with a subsequently 216 suggested target plasma CIT concentration in excess of 37µmol/L (37) . This has been 217 partially tested in children undergoing surgical procedures for congenital heart lesions. 218
Oral CIT supplements safely increased plasma CIT and ARG concentrations compared 219 with placebo, and improved NO production (17) . The expected decreases in plasma CIT 220 and ARG concentrations after cardiopulmonary bypass seen in the placebo group were 221 prevented by CIT. This was associated with a decreased risk of postoperative pulmonary 222 hypertension (15% in those treated with CIT compared to 30% in the controls). It was 223 thought that this effect was causally derived from the production of L-ARG from CIT, 224 and to stimulation of NO pathway in the hepatic and pulmonary tissues. The cytosolic 225 portion of the urea cycle was thought to be enabling localized, intracellular production ofM A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
14 L-ARG from CIT within the pulmonary endothelium as well as in hepatocytes. Curiously 227 these papers, which report on work from more than a decade ago, do not seem to have 228 been followed-up by their authors or others in the field (38, 39) .
229
Electrophysiological mechanisms may also be important. A study in healthy individuals 230
given CIT (3.2g 60-90 minutes before testing) demonstrated a reduction in QT interval on 231 electrocardiography, indicative of a shortening of the time required to de/repolarize the 232 myocardium (40) .
233
Taken as a whole these results are impressive but most enrolled a limited number of 234 subjects and only surrogate markers were studied. The time appears ripe for study of 235 larger cohorts of patients and evaluating the effects of CIT on morbidity and mortality. 236
237
Anabolic effects 238
Through various underlying mechanisms, CIT has the potential to affect protein 239 metabolism (41) . Osowska et al (42) showed that when malnourished elderly rats were re-240 fed with a CIT-enriched diet, muscle protein synthesis was greater, while hepatic protein 241 synthesis was less than in control rats fed an isonitrogenous supplement of non-essential 242 amino acids (NEAA). These data are now being supported by human studies of muscle 243 protein synthesis (43) . Eight healthy participants were investigated in a crossover study in 244 which, following 3 days of standardised low protein intake, CIT or a NEAA mixture was 245 given orally as small boluses over the course of 8 hours. Stable isotopes of phenylalanine 246 whole-body protein turnover did not differ between the two phases of the study (43) .
252
In a randomized controlled study of 10 healthy subjects, oral CIT supplementation was 253 associated with a 57% improvement in nitrogen balance at 12 hours (from 683 (±246) to 254 970 (±187) mmol nitrogen/12 h; p=0.0053 for the comparison with placebo) (15) .
255
In a more recent study (44) on sixty-six healthy volunteers, supplementation with CIT and 256 reduced glutathione were associated with an improvement in cGMP activity, suggesting 257 direct effects on muscle protein synthesis and muscle performance. As in Jourdan's study 258 (43) , in a further study (45) of healthy, well-nourished volunteers, oral CIT could not be 259
shown to affect whole-body protein kinetics in the post-absorptive state. 260
Muscle protein synthesis contributes only about 25% of whole body protein synthesis (34) 261 and an increase of (for example) 20% in muscle protein synthesis would therefore 262 contribute less than a 7% increment in whole body protein synthesis. Together with 263
Osowska's data (42) of lower hepatic protein synthesis rates in rats fed with CIT, this may 264 explain the apparent lack of a CIT effect at the whole-body level despite a statistically 265 significant effect on muscle protein synthesis. Bouillanne et al (46) show, in a prospective 266 randomized multicentre study, that 3-week's CIT supplementation (10 g/day) in 29 267 moderately malnourished elderly subjects led to higher muscle mass and fat free mass, 268 M A N U S C R I P T
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16 and lower fat mass than controls supplemented with NEAA, whereas whole body protein 269 synthesis was similar in the two groups. In other words, the effects of CIT on nitrogen 270 handling are neither ubiquitous nor uniform, and its anabolic effects are likely to be 271 specific to muscle. 272
However, in one study (47) of 22 healthy, elderly subjects, an effect of CIT on myofibrillar 273 protein synthesis was not confirmed. CIT co-ingestion with a low quantity (15 g) of 274
protein was ineffective in augmenting anabolism compared with NEAA. 275
Hyperargininaemia was interestingly demonstrated after ingestion of CIT in this study. 276
The mechanisms of action of CIT begin to be understood. Data suggest an involvement 277 of the mTOR (mammalian/mechanistic target of rapamycin) pathway in the effect of CIT 278 on protein synthesis (41, 48) . In general mTOR coordinates protein synthesis and 279 mitochondrial functions by selectively modulating synthesis of a series of nuclear-280 encoded mitochondrial proteins as well as by regulating mRNA translation (48) .
281
In addition, it has been shown that NOS activity is necessary for calcium-induced 282 activation of the Akt pathway (involved in translation initiation and thus muscle protein 283 synthesis) through a cGMP/PI3K-dependent pathway (49) . Nitrite has been shown to 284 enhance mTOR activity and cell proliferation of myoblasts (50) . CIT has relevance in both 285 of these contexts. 286
Conclusion 287
Exogenous CIT is a potent precursor for ARG and it functions as a donor of NO in many clinical contexts. Its administration appears safe but there are currently few clinical M A N U S C R I P T
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17 studies from which to draw conclusions on its therapeutic efficacy. Preliminary data indicate that it could be of value in systemic and pulmonary hypertension, in cardiac failure, in the management of arteriosclerosis, and in sarcopenia in the elderly (Table 1and 2). Several new clinical research studies have been designed to address these interesting possibilities and are on-going. 
